All articles tagged with #overall survival
In a trial for metastatic pancreatic cancer, Revolution Medicines' targeted pill daraxonrasib extended median overall survival to 13.2 months versus 6.7 months with chemotherapy, a dramatic near-doubling that experts described as very impressive.
Revolution Medicines announced that its pancreatic cancer drug daraxonrasib met all primary and secondary endpoints in a Phase 3 trial, nearly doubling median overall survival (13.2 months vs 6.7 months) and reducing the risk of death by about 60% versus chemotherapy, prompting an FDA filing using a Commissioner’s National Priority Voucher; safety was manageable and the company is pursuing second-line use and trials in newly diagnosed patients.
Datroway demonstrated a significant improvement in overall survival and progression-free survival in a Phase III trial for patients with metastatic triple-negative breast cancer who cannot receive immunotherapy, marking a potential breakthrough in treatment options for this high-risk group.
AstraZeneca's FLAURA2 Phase III trial shows that combining Tagrisso with chemotherapy significantly improves overall survival in patients with EGFR-mutated advanced non-small cell lung cancer, reinforcing Tagrisso as a key treatment option across stages.
A study published in Annals of Surgical Oncology reveals that implementing a multidisciplinary surgical approach significantly improves overall survival (OS) in patients with ovarian cancer. The study, conducted at Mater University Hospital, found that patients who underwent the new approach experienced a 70% improvement in OS compared to previous therapies. The multidisciplinary surgical team (MDT) approach, which involved collaboration among various surgical disciplines, aimed to eliminate all visible tumors within patients' abdomens. The study also identified residual disease and age as independent predictors of survival. The findings highlight the importance of a multidisciplinary approach in achieving optimal treatment outcomes and improved quality of life for ovarian cancer patients.
Merck's anti-PD-1 therapy, KEYTRUDA, has shown a statistically significant improvement in overall survival (OS) as adjuvant therapy for patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, according to the Phase 3 KEYNOTE-564 trial. This marks the first time a therapy has demonstrated a survival benefit compared to placebo in this patient population. The results build on the previously reported disease-free survival benefit from the same trial. KEYTRUDA's safety profile was consistent with previous studies, and the results will be presented at an upcoming medical meeting and submitted to regulatory authorities.